Novartis Oncology is conducting a clinical research study to evaluate the difference in effectiveness and safety between the investigational drug patupilone and the drug docetaxel, in people who have hormone refractory prostate cancer. The reason for this study is to find out which of these two medicines gives better relief of prostate cancer. Participants who agree to join in this study, may get either 10 mg/m2 patupilone once every three weeks or 75 mg/m2 of docetaxel once every three weeks, intravenously (directly into a vein). Prednisone will be given to all participants as supportive therapy. Patupilone is a medicine which has not been approved by the FDA (US Food and Drug Administration) for the treatment of people with prostate cancer. Docetaxel is a medication approved by the FDA to treat breast cancer, non-small cell lung cancer and prostate cancer. This study is open-label, which means that after participants are randomly assigned to a treatment, they will know which medication they are receiving.